Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Risk factors

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Back to table of contents Previous article Next article Clinical & Research NewsFull AccessFew Alzheimer’s Patients Get State-of-Art CareJim RosackJim RosackSearch for more papers by this authorPublished Online:20 Apr 2001https://doi.org/10.1176/pn.36.8.0042Preliminary data suggest that a huge treatment gap exists in patients with Alzheimer’s disease, with as many as 65 percent of patients with the progressive and terminal disorder going undiagnosed and, therefore, untreated.This startling finding was just one of many discussed and debated at the annual meeting of the American Association for Geriatric Psychiatry (AAGP) in San Francisco in February.Several researchers and clinicians from various disciplines noted, once again, that the majority of patients with AD are not being seen by specialists, but rather by primary care physicians who do not always recognize and treat the disease.The significance of the problem was summed up by P. Many physicians, he explained, see the progressive course of the disease as unrelenting and see no value to treatment.Geriatric psychiatry specialists “haven’t yet convinced primary care physicians of the value of treatment for dementia and cognitive disorders associated with AD,” Doraiswamy said. “They thus have no real impetus to diagnose the disorder. The result is a large number of last-minute diagnoses that even a grocery store clerk could have made.”According to Doraiswamy, research indicates that as many as two-thirds of all cases of dementia in the community are not recognized or evaluated. What they do not understand is that the value of the medication lies in the fact that without that six to 12 months of cholinesterase inhibitor therapy, the cognitive function of the patient would be significantly worse.”Cholinesterase inhibitors (ChEIs) have only been available since the mid 1990s. The result of that action is a relative increase in available acetylcholine within the synapses of the brain neurons affected by AD. More recently, rivastigmine tartrate (Exelon) gained approval in April 2000, and galantamine hydrobromide (Reminyl) was approved February 28 (Original article: see story on page 43).Several of the AAGP annual meeting presentations focused on the use of these medications as well as new and developing medications that could expand treatment options for AD.Significant evidence now suggests, Doraiswamy said, that ChEIs may ease the loss of independence that patients feel, improve the patients’ ability to condu

What this study adds

Evidence grade: Low

The record lists 125 participants. Preliminary data suggested that many Alzheimer's patients go undiagnosed and untreated, partly because primary care physicians may not see value in treatment. This concerns diagnosis and care gaps, not a treatment, cure, or prevention for the disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Rosack, J. (2001). Few Alzheimer’s Patients Get State-of-Art Care. Psychiatric News. https://doi.org/10.1176/pn.36.8.0042

Vancouver

Rosack J. Few Alzheimer’s Patients Get State-of-Art Care. Psychiatric News. 2001. doi:10.1176/pn.36.8.0042.

BibTeX

@article{rosack2001-d4990f60,
  author  = {Rosack, Jim},
  title   = {{Few Alzheimer’s Patients Get State-of-Art Care}},
  journal = {Psychiatric News},
  year    = {2001},
  doi     = {10.1176/pn.36.8.0042},
  url     = {https://doi.org/10.1176/pn.36.8.0042}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

Preliminary data suggested that many Alzheimer's patients go undiagnosed and untreated, partly because primary care physicians may not see value in treatment. This concerns diagnosis and care gaps, not a treatment, cure, or prevention for the disease.

Study details

How this study scored 27/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record left out, no data; Multicenter collaboration 0 of 3; Indexed in PubMed 1 of 2; Free to read 0 of 2. 26 of the 97 points it could be judged on, which is 27 of 100. Total 27 of 100.26 of the 97 points we could judge = 27 of 100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 26 of the 97 points we could judge it on, which is 27 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Psychiatric News)
Journal's citation record 0 / 4 Psychiatric News: journal h-index 17 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2001 — older than 20 years, still counted
Sample size 2 / 4 125 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 27 year(s) since 2001
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Jim Rosack: h-index 6 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 0 / 2 Behind a paywall — scores zero
Points 26 / 97 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 26 of the 97 points we could judge it on is 27 out of 100.
Total 27 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Risk factors from nearby years

Also in Risk factors

383 studies in the library are filed under Risk factors with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk factors hub.

Similar studies

More on Risk factors

See all studies in Risk factors →